Compare Biogen Inc (BIIB) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Sea Limited — how do they compare? Biogen Inc trades at $195.43 (market cap $28.34B), while Sea Limited trades at $112.25 (market cap $66.94B). The key difference: Sea Limited is far larger — about 2.4× Biogen Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals.
| BIIB | SE | |
|---|---|---|
Market Cap | $28.34B | $66.94B |
Sector | Health | Media |
52-Week High | $216.63 | $196.50 |
52-Week Low | $122.68 | $78.16 |
Enterprise Value | $30.62B | $59.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
SE trades at $110.66, down 0.43% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth, reaching $22.94B in 2025, and improving profitability with a net income margin of 6.36%. Recent earnings beat expectations in Q1 2026, but insider sales have drawn media attention. Cash flow turned positive in 2025 at $2.34B, reflecting operational strength.
Outlook remains positive with a consensus price target of $131, implying 18% upside. Risks include competitive pressures in Southeast Asia and execution on growth investments. Analyst sentiment is strongly bullish with 70% buy ratings, though high valuation multiples and recent insider selling warrant caution for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
